A New World of Targeted Therapies for HER2-Positive Breast Cancer Takes Shape
December 17th 2014When added to standard chemotherapy, trastuzumab not only dramatically improved disease-free survival rates for patients with metastatic disease, but also resulted in a clear survival advantage unprecedented for most treatments of metastatic breast cancer.
Read More